JP2015519355A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519355A5 JP2015519355A5 JP2015514499A JP2015514499A JP2015519355A5 JP 2015519355 A5 JP2015519355 A5 JP 2015519355A5 JP 2015514499 A JP2015514499 A JP 2015514499A JP 2015514499 A JP2015514499 A JP 2015514499A JP 2015519355 A5 JP2015519355 A5 JP 2015519355A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- tlr3
- binding
- tlr3 polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 23
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 4
- 102000045716 human TLR3 Human genes 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653652P | 2012-05-31 | 2012-05-31 | |
| US61/653,652 | 2012-05-31 | ||
| US201261670289P | 2012-07-11 | 2012-07-11 | |
| US61/670,289 | 2012-07-11 | ||
| US201261679923P | 2012-08-06 | 2012-08-06 | |
| US61/679,923 | 2012-08-06 | ||
| PCT/EP2013/061173 WO2013178736A1 (en) | 2012-05-31 | 2013-05-30 | Tlr3 binding agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519355A JP2015519355A (ja) | 2015-07-09 |
| JP2015519355A5 true JP2015519355A5 (https=) | 2016-06-02 |
| JP6356120B2 JP6356120B2 (ja) | 2018-07-11 |
Family
ID=48576992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514499A Expired - Fee Related JP6356120B2 (ja) | 2012-05-31 | 2013-05-30 | Ｔｌｒ３結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9944712B2 (https=) |
| EP (1) | EP2855527B1 (https=) |
| JP (1) | JP6356120B2 (https=) |
| CN (1) | CN104379603B (https=) |
| AU (1) | AU2013269652B2 (https=) |
| CA (1) | CA2874918A1 (https=) |
| DK (1) | DK2855527T3 (https=) |
| ES (1) | ES2695151T3 (https=) |
| MX (1) | MX361773B (https=) |
| WO (1) | WO2013178736A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2543095T3 (es) | 2009-07-10 | 2015-08-14 | Innate Pharma | Agentes de unión a TLR3 |
| EP2855527B1 (en) | 2012-05-31 | 2018-08-01 | Innate Pharma | Tlr3 binding agents |
| US20160136272A1 (en) * | 2013-05-14 | 2016-05-19 | Innate Pharma | Methods for restoring corticosteroid sensitivity |
| TWI788321B (zh) | 2017-01-20 | 2023-01-01 | 美商健臻公司 | 骨靶向抗體 |
| TW202506185A (zh) | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5491084A (en) | 1993-09-10 | 1996-02-13 | The Trustees Of Columbia University In The City Of New York | Uses of green-fluorescent protein |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AR006928A1 (es) | 1996-05-01 | 1999-09-29 | Pioneer Hi Bred Int | Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas. |
| ATE458053T1 (de) | 1997-05-07 | 2010-03-15 | Schering Corp | Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| WO2003080675A2 (en) | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| JP2004016021A (ja) | 2002-06-12 | 2004-01-22 | Japan Science & Technology Corp | 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット |
| AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| AR051836A1 (es) * | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
| DK1945820T3 (da) | 2005-10-27 | 2013-11-11 | Janssen Biotech Inc | Toll-lignende receptor-3-modulatorer, fremgangsmåder og anvendelser |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| US8354508B2 (en) | 2006-07-21 | 2013-01-15 | Diadexus, Inc. | PRO115 antibody compositions and methods of use |
| US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| EP2155249A4 (en) | 2007-05-15 | 2011-11-16 | Oncomed Pharm Inc | COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER |
| EP2238155A4 (en) * | 2007-12-26 | 2011-07-06 | Centocor Ortho Biotech Inc | CYNOMOLGUS TYPE TOLL 3 RECEIVER |
| CA2722589A1 (en) | 2008-04-25 | 2009-10-29 | Innate Pharma | Improved tlr3 agonist compositions |
| PE20110808A1 (es) | 2008-10-31 | 2011-10-31 | Janssen Biotech Inc | Anticuerpos contra el receptor 3 de tipo toll |
| US20130090457A1 (en) | 2008-10-31 | 2013-04-11 | Janssen Biotech, Inc. | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases |
| US8460659B2 (en) | 2008-10-31 | 2013-06-11 | Janssen Biotech, Inc. | Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases |
| EA021512B1 (ru) * | 2009-04-29 | 2015-07-30 | Янссен Байотек Инк. | Антагонисты толл-подобного рецептора 3 |
| ES2543095T3 (es) | 2009-07-10 | 2015-08-14 | Innate Pharma | Agentes de unión a TLR3 |
| DK2332986T3 (da) | 2009-12-11 | 2013-12-16 | Deutsches Krebsforsch | Antistof som binder til H-1 parvovirus |
| WO2012095432A2 (en) * | 2011-01-12 | 2012-07-19 | Innate Pharma | Tlr3 binding agents |
| EP2855527B1 (en) | 2012-05-31 | 2018-08-01 | Innate Pharma | Tlr3 binding agents |
-
2013
- 2013-05-30 EP EP13727110.2A patent/EP2855527B1/en not_active Not-in-force
- 2013-05-30 ES ES13727110T patent/ES2695151T3/es active Active
- 2013-05-30 MX MX2014014443A patent/MX361773B/es active IP Right Grant
- 2013-05-30 CN CN201380028786.1A patent/CN104379603B/zh not_active Expired - Fee Related
- 2013-05-30 DK DK13727110.2T patent/DK2855527T3/en active
- 2013-05-30 CA CA2874918A patent/CA2874918A1/en not_active Abandoned
- 2013-05-30 US US14/403,171 patent/US9944712B2/en active Active
- 2013-05-30 JP JP2015514499A patent/JP6356120B2/ja not_active Expired - Fee Related
- 2013-05-30 WO PCT/EP2013/061173 patent/WO2013178736A1/en not_active Ceased
- 2013-05-30 AU AU2013269652A patent/AU2013269652B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519355A5 (https=) | ||
| JP2017504577A5 (https=) | ||
| JP2014518883A5 (https=) | ||
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| JP2012143232A5 (https=) | ||
| JP2013518055A5 (https=) | ||
| JP2015508757A5 (https=) | ||
| JP2020521751A5 (https=) | ||
| JP2015537044A5 (https=) | ||
| JP2011500091A5 (https=) | ||
| JP2012012402A5 (https=) | ||
| RU2539774C3 (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| JP2017526632A5 (https=) | ||
| JP2016539096A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| RU2018128215A (ru) | Антитела против mica | |
| JP2016532693A5 (https=) | ||
| HRP20191483T1 (hr) | Protutijela koja reagiraju s b7-h3, njihovi imunološki aktivni fragmenti i njihova upotreba | |
| JP2016185981A5 (https=) | ||
| AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
| JP2007536932A5 (https=) | ||
| JP2010533498A5 (https=) | ||
| JP2013535190A5 (https=) | ||
| JP2016527286A5 (https=) |